The therapeutic potential of targeting the CHD protein family in cancer

被引：2

作者：

Zhang, Min ^{[1
]}

Wu, Kaiyuan ^{[5
,7
,8
]}

Zhang, Weijie ^{[2
,3
]}

Lin, Xia ^{[1
]}

Cao, Qi ^{[4
]}

Zhang, Lili ^{[5
,6
]}

Chen, Kaifu ^{[5
,6
,7
,9
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, Hangzhou 310058, Zhejiang, Peoples R China

[2] Zhejiang Univ, Life Sci Inst, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed Surg, Hangzhou 310058, Zhejiang, Peoples R China

[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA

[5] Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA

[6] Harvard Univ, Dana Farber & Harvard Canc Ctr, Prostate Canc Program, Boston, MA 02115 USA

[7] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA

[8] Rice Univ, Dept Bioengn, Houston, TX 77005 USA

[9] 300 Longwood Ave, Mailstop BCH3109, Boston, MA 02115 USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2024年 / 256卷

关键词：

Epigenetic regulation; Cancer development; Chromatin remodeling; Therapeutic strategies; DNA METHYLTRANSFERASE INHIBITORS; AURORA-B; PROSTATE-CANCER; CELL-PROLIFERATION; DAMAGE RESPONSE; BREAST-CANCER; CHROMATIN; EZH2; BINDING; TRANSCRIPTION;

D O I：

10.1016/j.pharmthera.2024.108610

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-offunction mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment. (c) 2024 Elsevier Inc. All rights reserved.

引用

页数：10

共 109 条

[11] SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis [J].